**Baseline Monitoring**

- Complete blood count and hemogram

- Erythrocyte sedimentation rate or C-reactive protein

- Liver function test

- Renal function test and urinalysis

- Serum electrolytes

- Anti-nuclear and anti-dsDNA antibodies

- Screening for hepatitis and HIV infection

- Chest X-ray

- Tuberculin skin testing or Quantiferon Gold test

- Pregnancy test in females of childbearing age

- Serology for varicella-zoster and measles. (if clinically indicated)

**Ongoing Monitoring**

Evaluation of response to treatment is measurable by respective assessment scores, i.e., Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) at three months initially and subsequently every six months. A complete blood count and hemogram should be repeated at three months and every six months. Liver function tests, renal function tests, serum electrolytes, and urinalysis evaluations should be monitored at three months and every six months.